NPS Pharmaceuticals, Inc.  

(Public, NASDAQ:NPSP)   Watch this stock  
Find more results for GEORGE A. NADER�
-2.15 (-7.39%)
Oct 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 25.56 - 28.49
52 week 21.60 - 39.68
Open 27.50
Vol / Avg. 5.99M/2.09M
Mkt cap 3.10B
P/E 1,386.71
Div/yield     -
EPS 0.02
Shares 106.56M
Beta 0.82
Inst. own 102%
Nov 5, 2014
Q3 2014 NPS Pharmaceuticals Inc Earnings Release - Tentative Add to calendar
Oct 1, 2014
NPS Pharmaceuticals Inc at Leerink Rare Disease Roundtable
Sep 12, 2014
NPS Pharmaceuticals Inc Conference Call to discuss FDA Advisory Committee to Review Natpara� Biologics License Application
Sep 12, 2014
NPS Pharmaceuticals Inc FDA Advisory Committee Meeting
Aug 14, 2014
NPS Pharmaceuticals Inc at Canaccord Genuity Growth Conference - Webcast
Aug 12, 2014
NPS Pharmaceuticals Inc at Wedbush Securities Life Sciences Conference - Webcast
Aug 6, 2014
Q2 2014 NPS Pharmaceuticals Inc Earnings Call - Webcast
Aug 6, 2014
Q2 2014 NPS Pharmaceuticals Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 3.55% -8.68%
Operating margin 10.32% -0.96%
EBITD margin - 0.73%
Return on average assets 2.82% -6.09%
Return on average equity 6.82% -53.75%
Employees 207 -
CDP Score - -


United States - Map
+1-908-4505300 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The Company�s primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved by the United States Food and Drug Administration (FDA) during the year ended December 31, 2012, for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. Natpara is the recombinant full-length human parathyroid hormone (rhPTH (1-84)), which is developing as a hormone replacement therapy for hypoparathyroidism, a rare hormone deficiency disorder, in which patients are physiologically unable to regulate the levels of calcium and phosphates in their blood due to insufficient levels of endogenous parathyroid hormone (PTH).

Officers and directors

Peter G. Tombros Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Francois Nader M.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Luke M. Beshar CPA Chief Financial Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
Roger J. Garceau M.D. Executive Vice President, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Christine Mikail Senior Vice President - Legal Affairs, General Counsel
Bio & Compensation  - Reuters
Glenn R. Melrose Senior Vice President - Human Resources
Age: 58
Bio & Compensation  - Reuters
Eric Pauwels Chief Commercial Officer, Senior Vice President
Age: 52
Bio & Compensation  - Reuters
Joseph J. Rogus Vice President - Technical Operations and Supply Chain Management
Age: 67
Bio & Compensation  - Reuters
Susan E. Graf Vice President - Corporate Development and Strategy
Age: 41
Bio & Compensation  - Reuters
Michael W. Bonney Independent Director
Age: 55
Bio & Compensation  - Reuters